Liquidia
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
419 Davis Dr Ste 100, Morrisville, North...Phone Number
(919) 328-4400Website
www.liquidia.comRevenue
$288.1 MillionStock Symbol
LQDAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Liquidia
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC.Explore more
Liquidia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Liquidia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Liquidia recently announced quarterly report
Product Launch: Get notified when Liquidia launches new products
Liquidia, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Liquidia is spiking on competitors!
Check if Liquidia has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Liquidia
Funding: Get notified immidiatlly once Liquidia has new funding data
Click to see if Liquidia had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Liquidia as Masked Content
Find 2 more new buyers
Compare Similar Companies to Liquidia
Compare insights from companies similar to Liquidia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Liquidia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Liquidia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Liquidia.
Liquidia financials insights
Gather financial insights about Liquidia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series A
$6M
2007
Series B
$16M
2010
Series C
$25M
2018
Series D
$25.5M
2021
Debt
$20.5M
2022
Debt
$40M
2025
Debt
$100M
Liquidia Tech Stack
A closer look at the technologies used by Liquidia
Most Recent Scoops
Person-Based
Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Facilities Relocation / Expansion
Liquidia has announced plans to expand its YUTREPIA manufacturing capacity by building a new facility in North Carolina, which will nearly triple the company's current production capacity.
Facilities Relocation/Expansion, Capacity Planning, Manufacturing Operations
Pain Point
Liquidia is facing a legal risk related to the Hikma versus Amarin case, which has been brought to the U.S. Supreme Court and was cited by United Therapeutics in post-trial briefing against Liquidia, with a Supreme Court opinion expected by the end of June or early July.
Lawsuits, Legal Affairs
Project
Artificial Intelligence
Liquidia News & Media
Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential
Buckley Capital Advisors, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter delivered strong, broad-based gains across the portfolio, with several of the Fund’s largest positions contributing to performance. Buckley Capital returned 36.0% net during the quarter and 29.7% net year-to-date, outperforming […]Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […]Is Liquidia Corporation (LQDA) A Good Stock To Buy Now?
Is LQDA a good stock to buy? We came across a bullish thesis on Liquidia Corporation on r/GrowthStockInvesting by symbaeu. In this article, we will summarize the bulls’ thesis on LQDA. Liquidia Corporation’s share was trading at $76.92 as of June 25th. LQDA’s trailing and forward P/E were 444.35 and 36.36 respectively according to Yahoo Finance. Liquidia […]Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Liquidia Corporation (LQDA) Shareholder/Analyst Call June 16, 2026 4:30 PM EDTCompany ParticipantsRoger Jeffs - CEO & DirectorRussell Schundler -...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Liquidia
Sign Up For FreeTo access detailed company insights
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of... Read More
